title: [Systemic therapy for malignant melanoma].
abstract: For decades dacarbazine was the standard in the therapy for metastatic melanoma even though response rates were low. In recent years multiple pharmacological approaches have led to new therapy options including immune modulators like anti-CTLA4 antibodies and kinase inhibitors of the MAPK signaling pathway that showed better response rates and increased overall survival. However, since immune modulators lead only in a small subgroup of patients to long-term responses and kinase inhibitors lose their function due to development of resistance after several months, continuation of clinical studies is strongly required. Classical chemotherapeutic drugs will remain a basic part of the therapy especially as combinations of different treatment options have to be focused on in order to achieve better long-term survival rates.
authors.affiliation: Hautklinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland.
authors.forename: B M
authors.initials: BM
authors.lastname: Rudolph
authors.forename: A
authors.initials: A
authors.lastname: Groffik
authors.forename: C
authors.initials: C
authors.lastname: Stanger
authors.forename: C
authors.initials: C
authors.lastname: Loquai
authors.forename: S
authors.initials: S
authors.lastname: Grabbe
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000639:trends*; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007155:Immunologic Factors